Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience

Indian Journal of Cancer
R TippeswamyK M Haridas

Abstract

Neuroendocrine tumors (NETs) are rare, heterogeneous, indolent tumors that are relatively insensitive to systemic chemotherapy. Therapeutic strategies for NETs broadly include somatostatin analogs, antiangiogenic therapy, and most recently, mammalian target of rapamycin inhibition. Combination therapy has shown promising antitumor activity and good tolerability in the randomized phase III trials. The aim was to evaluate the safety and efficacy of Everolimus plus Octreotide long-acting repeatable (LAR) in patients with advanced NETs in the routine tertiary cancer care setting in India in this postapproval, noninterventional trial. Patients presenting to selected centers between 2011 and 2013 with histologically confirmed low-, intermediate- or high-grade advanced NETs who may have had prior exposure to cytotoxic chemotherapy (≤2 lines) were treated with oral Everolimus (10 mg/day) plus intramuscular Octreotide LAR (30 mg once every 28 days) until disease progression or unacceptable toxicity was seen. Patients were evaluated every 3 months for a response to therapy as per Response Evaluation Criteria in Solid Tumors. Everolimus plus Octreotide LAR was associated with a clinical benefit rate of 69% (best evaluable responses: Stabl...Continue Reading

References

Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Oct 29, 2005·Best Practice & Research. Clinical Gastroenterology·Kjell Oberg, Barbro Eriksson
Dec 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F PanzutoG Delle Fave
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoJaffer A Ajani
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoBertram Wiedenmann
Jun 24, 2010·World Journal of Gastroenterology : WJG·Jonathan Strosberg, Larry Kvols
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 12, 2011·Cancer Metastasis Reviews·Kjell Oberg, Daniel Castellano

❮ Previous
Next ❯

Citations

Apr 14, 2017·Journal of Cancer Research and Clinical Oncology·Marco GalloUNKNOWN NIKE Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.